Top

Published in:

01-10-2017 | Original Paper

Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach

Authors: R. Ragheb, G. Venton, R. Chelbi, N. Bonnet, T. Le Treut, V. Ivanov, C. Mercier, P. Poulin, N. Beaufils, J. Gabert, P. Suchon, P. Rihet, B. Loriod, B. Kahn-Perlès, Régis T. Costello

Published in: Archives of Dermatological Research | Issue 8/2017

Abstract

SAHA (vorinostat) is a histone deacetylase inhibitor approved by the USA Food and Drug Administration (FDA) for treating advanced refractory cutaneous T cell lymphomas. As SAHA alters the expression of many genes under control of the Sp1 transcription factor, we examined the effect of its association with the FDA-approved anticancer antibiotic Mithramycin A (MTR, plicamycin), a competitive inhibitor of Sp1 binding to DNA. Sézary syndrome (SS) cells, expanded ex vivo from peripheral blood mononuclear cells of 4 patients, were tested for their sensitivity to the drugs regarding cytotoxicity and differential responsive gene expression. Multivariate statistical methods were used to identify genes whose expression is altered by SAHA, MTR, and the synergist effect of the two drugs. MTR, like SAHA, induced the apoptosis of SS cells, while the two drugs in combination showed clear synergy or potentiation. Expression data stressed a likely important role of additive or synergistic epigenetic modifications in the combined effect of the two drugs, while direct inhibition of Sp1-dependent transcription seemed to have only limited impact. Ontological analysis of modified gene expression suggested that the two drugs, either independently or synergistically, counteracted many intertwined pro-survival pathways deregulated in SS cells, resistance of these tumors to intrinsic and extrinsic apoptosis, abnormal adhesion migration, and invasive properties, as well as immunosuppressive behavior. Our findings provide preliminary clues on the individual and combined effects of SAHA and MTR in SS cells and highlight a potential therapeutic interest of this novel pair of drugs for treatment of SS patients.

Available only for authorised users

Barba G, Matteucci C, Girolomoni G et al (2008) Comparative genomic hybridization identifies 17q11.2 approximately q12 duplication as an early event in cutaneous T-cell lymphomas. Cancer Genet Cytogenet 184:48–51. doi:10.1016/j.cancergencyto.2008.03.007 CrossRefPubMed

Bellei B, Pacchiarotti A, Perez M, Faraggiana T (2004) Frequent beta-catenin overexpression without exon 3 mutation in cutaneous lymphomas. Mod Pathol 17(10):1275–1281CrossRefPubMed

Blume SW, Snyder RC, Ray R et al (1991) Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Investig 88:1613–1621. doi:10.1172/JCI115474 CrossRefPubMedPubMedCentral

Campbell JJ, Clark RA, Watanabe R, Kupper TS (2010) Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116:767–771. doi:10.1182/blood-2009-11-251926 CrossRefPubMedPubMedCentral

Campo E, Swerdlow SH, Harris NL et al (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032. doi:10.1182/blood-2011-01-293050 CrossRefPubMedPubMedCentral

Capriotti E, Vonderheid EC, Thoburn CJ et al (2007) Chemokine receptor expression by leukemic T cells of cutaneous T-cell lymphoma: clinical and histopathological correlations. J Investig Dermatol 127:2882–2892. doi:10.1038/sj.jid.5700916 CrossRefPubMed

Chou T-C (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621–681. doi:10.1124/pr.58.3.10 CrossRefPubMed

Contassot E, Kerl K, Roques S et al (2008) Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 111:4780–4787. doi:10.1182/blood-2007-08-109074 CrossRefPubMed

Costello R, Sanchez C, Le Treut T et al (2010) Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations. Br J Haematol 150:21–27. doi:10.1111/j.1365-2141.2009.07977.x CrossRefPubMed

10.

Dalloul A, Laroche L, Bagot M et al (1992) Interleukin-7 is a growth factor for Sézary lymphoma cells. J Clin Investig 90:1054–1060. doi:10.1172/JCI115920 CrossRefPubMedPubMedCentral

11.

Didier G, Brézellec P, Remy E, Hénaut A (2002) GeneANOVA—gene expression analysis of variance. Bioinform Oxf Engl 18:490–491CrossRef

12.

Duvic M, Vu J (2007) Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16:1111–1120. doi:10.1517/13543784.16.7.1111 CrossRefPubMed

13.

Gardner JM, Introcaso CE, Nasta SD et al (2009) A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome. J Am Acad Dermatol 61:112–116. doi:10.1016/j.jaad.2008.11.889 CrossRefPubMed

14.

Gotea V, Ovcharenko I (2008) DiRE: identifying distant regulatory elements of co-expressed genes. Nucleic Acids Res 36:W133–W139. doi:10.1093/nar/gkn300 CrossRefPubMedPubMedCentral

15.

Huang DW, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37:1–13. doi:10.1093/nar/gkn923 CrossRef

16.

Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57. doi:10.1038/nprot.2008.211 CrossRef

17.

Huang L, Sowa Y, Sakai T, Pardee AB (2000) Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19:5712–5719. doi:10.1038/sj.onc.1203963 CrossRefPubMed

18.

Iraci N, Diolaiti D, Papa A et al (2011) A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res 71:404–412. doi:10.1158/0008-5472.CAN-10-2627 CrossRefPubMed

19.

Kari L, Loboda A, Nebozhyn M et al (2003) Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 197:1477–1488. doi:10.1084/jem.20021726 CrossRefPubMedPubMedCentral

20.

Krejsgaard T, Odum N, Geisler C et al (2012) Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome. Leukemia 26:424–432. doi:10.1038/leu.2011.237 CrossRefPubMed

21.

Kim EJ, Hess S, Richardson SK et al (2005) Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Investig 115:798–812. doi:10.1172/JCI24826 CrossRefPubMedPubMedCentral

22.

Kim S-N, Kim NH, Lee W et al (2009) Histone deacetylase inhibitor induction of P-glycoprotein transcription requires both histone deacetylase 1 dissociation and recruitment of CAAT/enhancer binding protein beta and pCAF to the promoter region. Mol Cancer Res 7:735–744. doi:10.1158/1541-7786.MCR-08-0296 CrossRefPubMed

23.

Lee CS, Ungewickell A, Bhaduri A et al (2012) Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. Blood 120:3288–3297. doi:10.1182/blood-2012-04-423061 CrossRefPubMedPubMedCentral

24.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods San Diego Calif 25:402–408. doi:10.1006/meth.2001.1262 CrossRef

25.

Mir MA, Majee S, Das S, Dasgupta D (2003) Association of chromatin with anticancer antibiotics, mithramycin and chromomycin A3. Bioorg Med Chem 11:2791–2801CrossRefPubMed

26.

Nakayama A, Odajima T, Murakami H et al (2001) Characterization of two promoters that regulate alternative transcripts in the microtubule-associated protein (MAP) 1A gene. Biochim Biophys Acta 1518:260–266CrossRefPubMed

27.

Narducci MG, Scala E, Bresin A et al (2006) Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 107:1108–1115. doi:10.1182/blood-2005-04-1492 CrossRefPubMed

28.

Ritchie ME, Phipson B, Wu D et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. doi:10.1093/nar/gkv007 CrossRefPubMedPubMedCentral

29.

Rivero S, Ruiz-García A, Díaz-Guerra MJM et al (2011) Characterization of a proximal Sp1 response element in the mouse Dlk2 gene promoter. BMC Mol Biol 12:52. doi:10.1186/1471-2199-12-52 CrossRefPubMedPubMedCentral

30.

Shao Y, Gao Z, Marks PA, Jiang X (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101:18030–18035. doi:10.1073/pnas.0408345102 CrossRefPubMedPubMedCentral

31.

Tajrishi MM, Shin J, Hetman M, Kumar A (2014) DNA methyltransferase 3a and mitogen-activated protein kinase signaling regulate the expression of fibroblast growth factor-inducible 14 (Fn14) during denervation-induced skeletal muscle atrophy. J Biol Chem 289:19985–19999. doi:10.1074/jbc.M114.568626 CrossRefPubMedPubMedCentral

32.

Wozniak MB, Villuendas R, Bischoff JR et al (2010) Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 95:613–621. doi:10.3324/haematol.2009.013870 CrossRefPubMedPubMedCentral

33.

Wu J, Nihal M, Siddiqui J et al (2009) Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Investig Dermatol 129:1165–1173. doi:10.1038/jid.2008.30931 CrossRefPubMed

34.

Zhang Q, Nowak I, Vonderheid EC et al (1996) Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 93:9148–9153CrossRefPubMedPubMedCentral

Title: Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach
Authors: R. Ragheb
G. Venton
R. Chelbi
N. Bonnet
T. Le Treut
V. Ivanov
C. Mercier
P. Poulin
N. Beaufils
J. Gabert
P. Suchon
P. Rihet
B. Loriod
B. Kahn-Perlès
Régis T. Costello
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: Archives of Dermatological Research / Issue 8/2017
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-017-1761-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2017

High-frequency ultrasonography in objective evaluation of the efficacy of PUVA and UVA 1 phototherapy in mycosis fungoides

IL-36 cytokines are increased in acne and hidradenitis suppurativa

Topical application of palmitoyl-RGD reduces human facial wrinkle formation in Korean women

Understanding the phenotypic similarities between IFAP and Olmsted syndrome from a molecular perspective: the interaction of MBTPS2 and TRPV3

Topically used herbal products for the treatment of hair loss: preclinical and clinical studies

Association between serum/plasma adiponectin levels and immune-mediated diseases: a meta-analysis